Breaking News, Collaborations & Alliances

Roche’s MabThera Launch Triggers $5M Halozyme Milestone

Marks second product to use Halozyme's Enhanze technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche’s MabThera SC has launched in Europe, triggering a $5 million milestone payment to Halozyme Therapeutics under the companies’ license and collaboration agreement. In addition to Herceptin SC, MabThera SC is the second subcutaneous formulation of one of Roche’s oncology products to use Halozyme’s Enhanze (recombinant human hyaluronidase) technology.   MabThera SC is approved for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This formulatio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters